---
schema_version: "secwatch.filing_event.v1"
accession: "0001725160-23-000137"
form_type: "8-K"
ticker: "ZNTL"
cik: "0001725160"
company_name: "Zentalis Pharmaceuticals, Inc."
filed_at: "2023-06-15T23:59:59+00:00"
generated_at: "2026-06-14T00:23:19.129963+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Zentalis regains global rights to azenosertib, ZN-d5, ZN-c5 from Zentera

## Summary
- Terminated collaboration with Zentera Therapeutics; now holds worldwide development/commercialization rights to three drug candidates.
- Pays $30M upfront, milestone payment, and low single-digit royalty on Greater China net sales of azenosertib, ZN-d5, ZN-c5.
- Sold its 40.3% equity stake in Zentera back to Zentera for de minimis consideration.

## SEC filing metadata
- accession: 0001725160-23-000137
- form_type: 8-K
- ticker: ZNTL
- cik: 0001725160
- company_name: Zentalis Pharmaceuticals, Inc.
- filed_at: 2023-06-15T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1725160/000172516023000137/0001725160-23-000137-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1725160/000172516023000137/zntl-20230615.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001725160-23-000137
- JSON: https://secwatch.observer/filing/0001725160-23-000137.json
- Plain text: https://secwatch.observer/filing/0001725160-23-000137.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.